trifluridine
Trifluridine (also called trifluorothymidine; abbreviation TFT or FTD) is an anti-herpesvirus antiviral drug, used primarily as prescription eyedrops. It was sold under the trade name Viroptic by Glaxo Wellcome, now merged into GlaxoSmithKline. The brand is now wholly owned by King Pharmaceuticals.
Research
1,218 papers- Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial.The Lancet. Oncology · 2018
- Trifluridine/tipiracil in the treatment of gastric cancer.Future oncology (London, England) · 2022
- Trifluridine/tipiracil (FTD/TPI) and regorafenib in older patients with metastatic colorectal cancer.Journal of geriatric oncology · 2023
- Trifluridine/tipiracil for the treatment of metastatic gastric cancer.Expert review of gastroenterology & hepatology · 2020
- Trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancers.Future oncology (London, England) · 2018
via PubMed
Article
10 sectionsContents
- Medical uses
- Adverse effects
- Interactions
- Pharmacology
- Mechanism of action (eye drops)
- Pharmacokinetics (eye drops)
- Pharmacokinetics (oral)
- Chemistry
- References
- External links
Trifluridine (also called trifluorothymidine; abbreviation TFT or FTD) is an anti-herpesvirus antiviral drug, used primarily as prescription eyedrops. It was sold under the trade name Viroptic by Glaxo Wellcome, now merged into GlaxoSmithKline. The brand is now wholly owned by King Pharmaceuticals.
Trifluridine was approved for medical use in 1980. It is also a component of the anti-cancer drug trifluridine/tipiracil, which is taken by mouth.